

BLUE SHIELD OF CALIFORNIA FOUNDATION

California Technology Assessment Forum

February 16, 2011

Mission Bay Conference Center, San Francisco

SUMMARY OF PANEL ACTIONS

1. Call to Order and Welcome to Guests – Dan Ulyot, M.D.
2. Voted to approve the minutes from October 13, 2010 CTAF meeting
3. Technology Assessment Criteria review – Judith Walsh, M.D.
4. Fourteen members of the CTAF panel were in attendance. This provided a quorum. The CTAF panel took the following actions:

A. Safety and Effectiveness of Inferior Vena Cava Filters Used to Protect Against Pulmonary Embolism

The following recommendation was moved and seconded for CTAF panel for consideration:

- **It is recommended that the use of IVC filters to protect against pulmonary embolism does not meet CTAF criteria 3, 4 or 5 for safety, effectiveness and improvement in health outcomes**
- Following Panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.
- The panel voted fourteen (unanimous) in favor of the recommendation. The motion carried.

B. Vertebroplasty as a Treatment of Osteoporotic Compression Fractures (an update based on the VERTOS II trial)

The following recommendation was put before the CTAF panel for consideration:

- **It is recommended that vertebroplasty does not meet CTAF criteria 3-5 for safety, effectiveness and improvement in health outcomes for the treatment of osteoporotic vertebral compression fractures.**
- Following Panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.
- The CTAF panel voted thirteen in favor of the recommendation and one vote in dissent against the recommendation. The motion carried.

C. Therapeutic Hypothermia Following Cardiac Arrest

The following recommendation was put before the CTAF panel for consideration:

- **It is recommended that use of therapeutic hypothermia in comatose adults following cardiac arrest with a first rhythm of ventricular fibrillation or ventricular tachycardia meets CTAF TA Criterion 1 through 5 for improvement in health outcomes.**
- Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.
- The panel voted fourteen (unanimous) in favor of the recommendation. The motion carried.

D. Vitamin D for the Prevention of Osteoporotic Fractures

The following recommendation was put before the CTAF panel for consideration:

- The original recommendation was as follows: “It is recommended that use of vitamin D combined with calcium meets CTAF TA Criterion 1 through 5 for safety, effectiveness and improvement in health outcomes.”
- After discussion, the panel decided to include new wording to specifically clarify the following recommendation: **“It is recommended that use of vitamin D combined with calcium meets CTAF TA Criterion 1 through 5 for safety, effectiveness and improvement in health outcomes for the prevention of osteoporotic fractures.”**
 - The panel voted on the above recommendation.
- Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.
- The panel voted twelve in favor of the recommendation and two in dissent against the recommendation. The motion carried.

The meeting was adjourned at 3:30 P.M. The next meeting of the California Technology Assessment Forum will be held on June 29, 2011 at the Sheraton Gateway Hotel in Los Angeles, California.